The clinical effectiveness agency for England and Wales says that it will not recommend bevacizumab for the first-line treatment of metastatic colorectal cancer, despite fresh efforts by the manufacturer to reduce the drug's cost.The National Institute for Health and Clinical Excellence said in draft guidance August 24 that though it had considered recent proposals by bevacizumab's manufacturer, Roche, to discount the drug (marketed as Avastin), the latest pricing scheme was so complex as to create...